Skip to content

SRP combined with povidone iodine rinse (Yisuxin) in the treatment of periodontitis: a randomized, open-labeled, positive drug and placebo parallel controlled clinical study

SRP combined with povidone iodine rinse (Yisuxin) in the treatment of periodontitis: a randomized, open-labeled, positive drug and placebo parallel controlled clinical study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050571
Enrollment
Unknown
Registered
2021-08-29
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

periodontitis

Interventions

Experimental group1:Rinse with povidone iodine rinse
Experimental group2:Rinse with compound chlorhexidine rinse
Control group:Rinse with saline

Sponsors

West China Stomatological Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years, no gender limitation; 2. There are at least 20 natural teeth in the mouth, and the Ramfjord index teeth (i.e. 16 teeth, 21 teeth, 24 teeth, 36 teeth, 41 teeth, 44 teeth) are natural teeth and have no missing and non-residual roots; 3. Attachment loss at the most severe interproximal site: 1-4mm; bone loss on imaging: 1/3 of the root and coronal (0-33%); no tooth loss due to periodontitis. Local complexity: maximum probing depth <= 5mm, mainly in patients with periodontitis with horizontal bone loss; 4. Must have good vision, physical movement and judgment ability; 5. Voluntarily participate in the trial and comply with the clinical trial requirements.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to iodine and other drugs related to this test; 2. Pregnant women and lactating women; 3. Those who have undergone periodontal treatment such as scaling and scaling within the past 3 months; 4. Those who have used hormones, antibiotics and other drugs within the past 2 weeks; 5. Liver function damage (ALT or AST >= 1.5 times the upper limit of normal); 6. Patients with renal insufficiency (Crea exceeds the upper limit of the normal value or Urea >= 1.5 times the upper limit of the normal value); 7. Abnormal thyroid function, blood disease, acute viral stomatitis, traumatic ulcer, neuropsychiatric system and other diseases; 8. The subjects participated in other clinical trials at the same time and did not reach the clinical endpoint; the subjects participated in other clinical trials within the past 3 months; 9. Other investigators believe that they are not eligible for inclusion.

Design outcomes

Primary

MeasureTime frame
bleeding index;plaque index;stain index;

Secondary

MeasureTime frame
pocket probe depth;clinical attachment loss;Markers of gingival crevicular fluid inflammation;Supragingival plaque microorganisms;Evaluation of subjects' satisfaction after medication;

Countries

China

Contacts

Public ContactDing Yi

West China Stomatological Hospital of Sichuan University

yiding2000@126.com+86 18602875710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026